LAVA Therapeutics N.V. (LVTX)
LVTX Stock Price Chart
Explore LAVA Therapeutics N.V. interactive price chart. Choose custom timeframes to analyze LVTX price movements and trends.
LVTX Company Profile
Discover essential business fundamentals and corporate details for LAVA Therapeutics N.V. (LVTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Mar 2021
Employees
34.00
Website
https://www.lavatherapeutics.comCEO
Stephen Allen Hurly
Description
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
LVTX Financial Timeline
Browse a chronological timeline of LAVA Therapeutics N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 9 Dec 2025
EPS estimate is -$0.23.
Earnings released on 13 Aug 2025
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%.
Earnings released on 14 May 2025
EPS came in at -$0.13 surpassing the estimated -$0.37 by +64.86%.
Earnings released on 28 Mar 2025
EPS came in at -$0.14 surpassing the estimated -$0.32 by +56.25%, while revenue for the quarter reached $5.17M , beating expectations by +106.68%.
Earnings released on 10 Dec 2024
EPS came in at -$0.46 falling short of the estimated -$0.33 by -39.39%.
Earnings released on 20 Aug 2024
EPS came in at -$0.31 surpassing the estimated -$0.33 by +6.06%.
Earnings released on 21 May 2024
EPS came in at -$0.02 surpassing the estimated -$0.25 by +92.00%, while revenue for the quarter reached $7.51M , beating expectations by +221.92%.
Earnings released on 20 Mar 2024
EPS came in at -$0.24 falling short of the estimated $0.16 by -250.00%, while revenue for the quarter reached $388.21K , missing expectations by -93.79%.
Earnings released on 16 Nov 2023
EPS came in at -$0.34 surpassing the estimated -$0.48 by +29.17%, while revenue for the quarter reached $55.91K .
Earnings released on 22 Aug 2023
EPS came in at -$0.48 matching the estimated -$0.48, while revenue for the quarter reached $5.61M , beating expectations by +796.99%.
Earnings released on 11 Apr 2023
EPS came in at -$0.57 falling short of the estimated -$0.52 by -9.62%, while revenue for the quarter reached $1.33M .
Earnings released on 24 Mar 2023
EPS came in at -$0.38 surpassing the estimated -$0.61 by +37.70%, while revenue for the quarter reached $2.84M , beating expectations by +1.04K%.
Earnings released on 16 Nov 2022
EPS came in at $0.04 surpassing the estimated -$0.13 by +130.77%, while revenue for the quarter reached $14.90M , beating expectations by +5.86K%.
Earnings released on 13 Sept 2022
EPS came in at -$0.31 surpassing the estimated -$0.61 by +49.18%, while revenue for the quarter reached $489.54K .
Earnings released on 17 May 2022
EPS came in at -$0.41 surpassing the estimated -$0.95 by +56.84%, while revenue for the quarter reached $1.13M , beating expectations by +39.02%.
Earnings released on 24 Mar 2022
EPS came in at -$0.38 matching the estimated -$0.38, while revenue for the quarter reached $1.21M , beating expectations by +92.40%.
Earnings released on 15 Nov 2021
EPS came in at -$0.27 surpassing the estimated -$0.33 by +18.18%, while revenue for the quarter reached $2.43M , beating expectations by +20.93%.
Earnings released on 16 Aug 2021
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $1.28M , beating expectations by +30.25%.
Earnings released on 20 May 2021
EPS came in at -$12.27 falling short of the estimated -$0.81 by -1.41K%, while revenue for the quarter reached $1.18M , missing expectations by -89.21%.
Earnings released on 26 Mar 2021
EPS came in at -$0.25 , while revenue for the quarter reached $1.14M .
Earnings released on 31 Dec 2020
EPS came in at -$0.13 , while revenue for the quarter reached $2.16M .
LVTX Stock Performance
Access detailed LVTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.